GlobeNewsWire · IMTX · October 24, 2026

Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting

Get the app for more

Explore stock news, insights and company research.